Document is current
Any future updates will be listed below
-
Authors
Mariz, Filipe Colaço
Bender, Noemi https://orcid.org/0000-0003-2542-9949
Anantharaman, Devasena
Basu, Partha
Bhatla, Neerja
Pillai, Madhavan Radhakrisna
Prabhu, Priya R.
Sankaranarayanan, Rengaswamy
Eriksson, Tiina
Pawlita, Michael https://orcid.org/0000-0002-4720-8306
Prager, Kristina
Sehr, Peter
Waterboer, Tim
Müller, Martin
Lehtinen, Matti
- License Information
-
More Information
Article History
Received: 10 August 2019
Accepted: 27 January 2020
First Online: 14 February 2020
Competing interests
: M.L. has received grants for HPV vaccination studies from Merck Sharp & Dohme and GlaxoSmithKline Biologicals through University of Tampere. M.M., M.P. and P.S. are inventors on a patent application by DKFZ on the high-throughput-pseudovirion-based neutralization assay (HT-PBNA). M.M. is an inventor of patents related to virus-like particle vaccines owned by Loyola University Chicago (Chicago, USA) and licensed to GlaxoSmithKline Biologicals. M.M. is an inventor of Trx-L2 vaccines and received personal fees from Merck Sharp & Dohme for analyses of clinical trial sera. N. Bhatla has received research funding from GlaxoSmithKline and Merck Sharp & Dohme through All India Institute of Medical Sciences. T.W. serves on advisory boards for MSD Sharpe & Dohme. The other authors declare no competing interests. P.B. and R.S. are staff members of the International Agency for Research on Cancer/World Health Organization. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.
